A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Launched by BRISTOL-MYERS SQUIBB · Jun 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BMS-986463 for patients with certain advanced cancers, specifically high-grade serous ovarian carcinoma, uterine serous carcinoma, and non-small cell lung cancer. The main goals of the study are to find out if the treatment is safe, how well it works, and to see how different doses affect patients. The trial is currently recruiting participants who are between the ages of 65 and 74, and both men and women can join.

To be eligible for this trial, participants need to have a certain level of health (measured by a performance status score) and must have at least one tumor that can be biopsied for testing. However, those with certain complications, like specific types of cancer spread to the brain, or those who have had previous cancers that needed treatment in the last two years, cannot participate. If you join the study, you can expect close monitoring and support from the medical team as you receive the treatment. Overall, this trial aims to explore a potentially new option for treating these advanced cancers.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
• • Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
• • Participants must have an unresectable/metastatic carcinoma.
• • Exclusion Criteria
• • Participants must not have Leptomeningeal metastases.
• • Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
• • Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
• • Other protocol-defined Inclusion/Exclusion criteria apply.